Evidence-based recommendations for the use of WBC-reduced cellular blood components

Transfusion

Volumn 41, Issue 10, 2001, Pages 1310-1319

  Ratko, Thomas A ^{a,b,c,d,e,f,g,h}   Cummings, Joseph P ^{a,b,c,d,e,f,g,h}   Oberman, Harold A ^{a,b,c,d,e,f,g,h}   Crookston, Kendall P ^{a,b,c,d,e,f,g,h}   DeChristopher, Phillip J ^{a,b,c,d,e,f,g,h}   Ted Eastlund, D ^{a,b,c,d,e,f,g,h}   Godwin, John E ^{a,b,c,d,e,f,g,h}   Sacher, Ronald A ^{a,b,c,d,e,f,g,h}   Yawn, David H ^{a,b,c,d,e,f,g,h}   Matuszewski, Karl A ^{a,b,c,d,e,f,g,h}  

^a University HealthSystem Consortium   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e LOYOLA UNIVERSITY CHICAGO   (United States)

^f Fairview University   (United States)

^g UNIVERSITY OF CINCINNATI   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD COMPONENT THERAPY; BLOOD DONOR; CONFERENCE PAPER; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; LEUKOCYTE; SAFETY; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED STATES; VASCULARIZATION;

BLOOD COMPONENT TRANSFUSION; BLOOD PRESERVATION; COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; HUMANS; LEUKAPHERESIS; RISK ASSESSMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; UNIVERSAL PRECAUTIONS;

EID: 0034773232     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2001.41101310.x     Document Type: Conference Paper

References (56)

1. Transfusion medicine. First of two parts - Blood transfusion
2. Improved utilization of blood due to systematic fractionation
3. Biotechnology, economics, and the business of blood
4. The impact of new clinical guidelines on the North American blood economy
5. Leukocyte reduction of cellular blood components. Effectiveness, benefits, quality control, and costs
6. A comparative analysis of different methods for routine blood component preparation
7. The use of leukocyte-reduced blood components
8. Leukocyte reduction of blood components: Public policy and new technology
9. The leukodepletion of cellular blood products in the prevention of HLA-alloimmunization and refractoriness to allogeneic platelet transfusions
10. Transfusion-associated cancer recurrence and postoperative infection: Meta-analysis of randomized, controlled clinical trials
11. Risk of allogeneic transfusions
12. Are allogeneic blood transfusions acceptable in elective surgery in colorectal carcinoma?
13. Risk of transmission of Creutzfeldt-Jakob disease by transfusion of blood, plasma, and plasma derivatives
14. Universal WBC reduction
15. Oversight and monitoring of blood safety in the United States
16. The periodic health examination: 1. Introduction
17. Rules of evidence and clinical recommendations on the use of antithrombotic agents
18. The evolution of guidelines
19. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction
20. A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia
21. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration
22. Prevention of refractoriness and HLA-alloimmunization using filtered blood products
23. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components - A randomized trial
24. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: A prospective, randomized trial
25. Bedside filtration of blood products in the prevention of HLA alloimmunization - A prospective, randomized study
26. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: A randomized prospective study
27. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions
28. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation
29. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products
30. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leukocytes
31. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors
32. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplantation
33. Prevention of transfusion-associated cytomegalovirus infection in neonatal patients by the removal of white cells from blood
34. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters
35. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant
36. Transfusion support Using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients
37. The cytomegalovirus-"safe" blood product: Is leuko reduction equivalent to antibody screening?
38. Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: The Viral Activation Transfusion Study: A randomized controlled trial
39. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery
40. Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer
41. Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery
42. Randomized trial comparing packed red cell blood transfusion with and without leukocyte depletion for gastrointestinal surgery
43. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: A randomized clinical trial
44. Deleterious clinical effects of transfusion-associated immunomodulation: Fact or fiction?
45. Universal WBC reduction: The case for and against
46. Transfusion-associated graft-versus-host disease
47. Pathophysiology of febrile nonhemolytic transfusion reactions
48. The role of the plasma from platelet concentrates in transfusion reactions
49. A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets
50. Transfusion medicine: An overview and update
51. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS)
52. The risk Of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study
53. Viral infections and the blood supply
54. The perils of plateiet transfusions
55. Will blood transfusion ever be safe enough?